{"id":3119,"date":"2026-04-03T15:26:14","date_gmt":"2026-04-03T15:26:14","guid":{"rendered":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/new-drug-shows-promise-in-reducing-lung-attack-flares-in-copd-patients\/"},"modified":"2026-04-03T15:26:14","modified_gmt":"2026-04-03T15:26:14","slug":"new-drug-shows-promise-in-reducing-lung-attack-flares-in-copd-patients","status":"publish","type":"post","link":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/new-drug-shows-promise-in-reducing-lung-attack-flares-in-copd-patients\/","title":{"rendered":"New Drug Shows Promise in Reducing Lung Attack Flares in COPD Patients"},"content":{"rendered":"

Two large clinical trials, called OBERON and TITANIA, have shown that a new medication called tozorakimab significantly reduces the number of moderate to severe lung attack flares in people with Chronic Obstructive Pulmonary Disease (COPD) compared to a placebo. These results were seen in both former smokers and a broader group of COPD patients, including current smokers, regardless of their blood eosinophil levels (a type of white blood cell) or how severe their lung function issues were. The drug was also found to be generally safe and well-tolerated by patients. <\/p>\n

Tozorakimab is a first-of-its-kind treatment that works by blocking a protein called interleukin-33 (IL-33). This protein plays a key role in causing inflammation and mucus buildup in the lungs, which worsens COPD symptoms. Unlike other similar drugs, tozorakimab targets both active and inactive forms of IL-33, aiming to break the cycle of inflammation and mucus that leads to COPD flare-ups. <\/p>\n

In the trials, patients who were already using standard inhaled treatments for COPD received either tozorakimab (300mg) or a placebo every four weeks. Even with these standard treatments, many COPD patients still experience flare-ups, which can lead to serious heart<\/a> and lung problems or even death. <\/p>\n

Professor Frank Sciurba, a lung specialis<\/a>t at the University of Pittsburgh and lead researcher of the LUNA program, said: \u201cThese results show that targeting the IL-33 pathway with tozorakimab provides real clinical benefits for a wide range of COPD patients, no matter if they currently smoke or their level of blood eosinophils. COPD is a complex disease to treat, and too many patients still suffer from flare-ups, hospitalizations, and life-threatening events. These findings are a significant step forward in improving COPD care.\u201d <\/p>\n

Sharon Barr, Executive Vice President of BioPharmaceuticals Research and Development at AstraZeneca, added: \u201cThese results from tozorakimab are the first successful phase 3 trials for a treatment that targets IL-33 in COPD, marking a major scientific breakthrough in a disease that is the third leading cause of death worldwide. Unlike other biologics, tozorakimab works by blocking both active and inactive forms of IL-33, which helps reduce inflammation and mucus buildup\u2014two key factors that drive COPD progression.\u201d <\/p>\n

The full details of these results will be shared at an upcoming medical conference. Additional large-scale trials, known as PROSPERO and MIRANDA, are still ongoing to further study tozorakimab. The drug is also being tested for its potential benefits in treating severe viral lung infections and asthma.<\/p>\n","protected":false},"excerpt":{"rendered":"

Two large clinical trials, called OBERON and TITANIA, have shown that a new medication called tozorakimab significantly reduces the number […]<\/p>\n","protected":false},"author":0,"featured_media":3120,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[543],"tags":[],"class_list":["post-3119","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical-news"],"_links":{"self":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/comments?post=3119"}],"version-history":[{"count":0,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3119\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/media\/3120"}],"wp:attachment":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/media?parent=3119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/categories?post=3119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/tags?post=3119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}